In conclusion, this real-world study substantiates the clinical efficacy of RC48 in both HER2-positive and HER2-low breast cancer, with differential therapeutic responses correlated to prior treatment exposure and metastatic site distribution. Here, ERBB2 is linked to breast cancer.